Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free GRDX Stock Alerts

Entero Therapeutics (GRDX) Financials

$2.88 +0.11 (+3.97%)
Closing price 04:00 PM Eastern
Extended Trading
$2.88 0.00 (-0.17%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Entero Therapeutics

Annual Income Statements for Entero Therapeutics

This table shows Entero Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.90 -9.93 -11 -14 -15 -42 -85 -15 -16 -18 -6.73
Consolidated Net Income / (Loss)		 -5.93 -15 -11 -14 -15 -33 -59 -15 -16 -18 -6.55
Net Income / (Loss) Continuing Operations		 -7.90 -9.93 -11 -14 -15 -33 -59 -15 -16 -16 -6.24
Total Pre-Tax Income 		-5.93 -15 -11 -14 -15 -33 -59 -15 -16 -16 -6.64
Total Operating Income		 -4.73 -6.33 -10 -13 -15 -26 -59 -13 -16 -16 -7.08
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.66
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04
Operating Revenue		 - - - 0.00 - - - - - 0.00 0.04
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.69
Operating Cost of Revenue		 - - - - - - - - - 0.00 0.69
Total Operating Expenses		 4.73 6.33 10 13 15 26 59 13 16 16 6.43
Selling, General & Admin Expense		 3.33 4.13 7.69 7.45 6.06 7.29 18 12 11 15 5.50
Research & Development Expense		 1.40 2.50 2.40 5.77 8.68 19 38 0.69 5.03 0.90 0.93
Total Other Income / (Expense), net		 -3.18 -3.61 -0.88 -0.10 -0.43 -6.24 0.52 -1.95 -0.02 0.00 0.44
Interest & Investment Income		 - - - - 0.00 0.00 0.00 0.01 -0.02 0.00 -0.49
Other Income / (Expense), net		 -1.59 -8.27 -0.88 - -0.43 0.21 0.53 -1.94 -0.00 0.00 0.93
Income Tax Expense		 0.00 0.00 - - 0.00 - - - - 0.00 -0.40
Net Income / (Loss) Discontinued Operations		 - - - - - - - - 0.00 -2.44 -0.31
Preferred Stock Dividends Declared		 - - - - 0.00 9.06 26 0.30 0.31 0.24 0.34
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - - - - 0.00 -0.16
Basic Earnings per Share		 ($1.63) ($2.24) ($1.04) $15,439,310.00 $22,425,564.00 ($14.68) ($1,988.53) ($416.94) ($47.88) ($15.99) ($4.16)
Weighted Average Basic Shares Outstanding		 3.63M 6.50M 10.63M -0.88 0.68 2.84M 42.50K 35.91K 336.34K 1.14M 1.62M
Diluted Earnings per Share		 ($1.63) ($2.24) ($1.04) $15,439,310.00 $22,425,564.00 ($14.68) ($1,988.53) ($416.94) ($47.88) ($15.99) ($4.16)
Weighted Average Diluted Shares Outstanding		 3.63M 6.50M 10.63M -0.88 0.68 2.84M 42.50K 35.91K 336.34K 1.14M 1.62M

Quarterly Income Statements for Entero Therapeutics

This table shows Entero Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -3.48 -4.18 5.50 -8.85 -2.67 -12 -1.34 -1.08 -1.24 -3.07 -3.63
Consolidated Net Income / (Loss)		 -3.43 -4.10 5.57 -8.81 -2.58 -12 -1.26 -1.00 -1.15 -3.14 -3.44
Net Income / (Loss) Continuing Operations		 -3.43 -4.10 -0.19 -7.69 -1.90 -5.85 -0.95 -0.67 -0.97 -4.28 -3.44
Total Pre-Tax Income 		-3.43 -4.10 -9.10 -3.43 -1.90 -1.19 -0.95 -0.67 -0.97 -4.05 -3.74
Total Operating Income		 -3.43 -4.09 -9.10 -3.43 -1.89 -1.20 -0.82 -0.64 -0.93 -4.69 -3.61
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 -0.66 -0.61
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.04 0.04
Operating Revenue		 - - - - - - 0.00 - - - 0.04
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 0.69 0.65
Operating Cost of Revenue		 - - - - - - 0.00 - - - 0.65
Total Operating Expenses		 3.43 4.09 9.10 3.43 1.89 1.20 0.82 0.64 0.93 4.03 3.00
Selling, General & Admin Expense		 2.42 2.79 8.54 3.21 1.69 1.28 0.81 0.63 0.93 3.14 2.37
Research & Development Expense		 1.01 1.31 0.55 0.22 0.21 -0.08 0.02 0.01 0.01 0.89 0.63
Total Other Income / (Expense), net		 -0.00 -0.01 -0.00 -0.00 -0.00 0.01 -0.13 -0.04 -0.04 0.64 -0.12
Interest & Investment Income		 - - 0.00 0.00 0.00 0.00 -0.02 -0.04 -0.04 -0.42 -0.52
Other Income / (Expense), net		 0.00 -0.00 -0.00 -0.00 -0.00 0.01 -0.11 0.00 0.00 1.04 0.40
Income Tax Expense		 0.00 - -15 4.26 0.00 11 0.00 0.00 0.00 -0.40 -0.30
Net Income / (Loss) Discontinued Operations		 0.00 - - -1.12 -0.69 - -0.31 -0.32 -0.18 - 0.00
Preferred Stock Dividends Declared		 0.05 0.08 0.07 0.04 0.08 0.05 0.08 0.08 0.09 0.08 0.08
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - - - 0.00 - - - 0.11
Basic Earnings per Share		 ($9.21) ($12.42) $3.12 ($3.86) ($1.76) ($10.73) ($0.84) ($0.21) ($0.75) ($1.90) ($0.82)
Weighted Average Basic Shares Outstanding		 378.30K 336.34K 1.76M 2.29M 1.52M 1.14M 1.59M 4.77M 1.65M 1.62M 4.45M
Diluted Earnings per Share		 ($9.21) ($12.42) $0.38 ($3.86) ($1.76) ($10.73) ($0.84) ($0.21) ($0.75) ($1.90) ($0.82)
Weighted Average Diluted Shares Outstanding		 378.30K 336.34K 14.51M 2.29M 1.52M 1.14M 0.00 4.77M 1.65M 1.62M 4.45M
Weighted Average Basic & Diluted Shares Outstanding		 13.50M 2.03M 2.48M - 4.75M 0.00 4.77M 4.77M 3.36M 0.00 6.65M

Annual Cash Flow Statements for Entero Therapeutics

This table details how cash moves in and out of Entero Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.49 1.20 -1.20 0.54 -0.91 5.91 2.16 -6.60 2.35 -3.55 0.71
Net Cash From Operating Activities		 -4.17 -4.53 -7.18 -11 -14 -11 -32 -22 -12 -9.22 -5.70
Net Cash From Continuing Operating Activities		 -2.11 -8.98 -7.12 -5.98 -14 -11 -32 -22 -12 -9.22 -5.70
Net Income / (Loss) Continuing Operations		 -5.93 -15 -11 -14 -15 -33 -59 -15 -16 -18 -6.55
Consolidated Net Income / (Loss)		 -5.93 -15 -11 -14 -15 -33 -59 -15 -16 -18 -6.55
Depreciation Expense		 0.04 0.04 0.05 0.06 0.06 0.04 0.01 0.03 0.03 0.05 0.57
Amortization Expense		 0.69 0.69 0.70 0.74 0.96 0.53 0.53 - 0.00 0.01 0.37
Non-Cash Adjustments To Reconcile Net Income		 1.43 8.62 3.43 3.58 1.74 20 23 -5.44 1.13 6.18 0.25
Changes in Operating Assets and Liabilities, net		 -0.40 0.70 -0.27 -1.71 -1.62 1.01 2.36 -2.31 2.26 2.61 -0.34
Net Cash From Investing Activities		 -0.02 -0.01 -0.03 -0.31 -0.02 0.09 -10 0.00 -0.50 0.09 0.32
Net Cash From Continuing Investing Activities		 -0.02 -0.01 -0.03 -0.31 -0.02 0.09 -10 0.00 -0.50 0.09 0.32
Divestitures		 - - - - - - - - 0.00 0.00 0.32
Other Investing Activities, net		 - - - - - - -10 0.00 -0.50 0.09 0.00
Net Cash From Financing Activities		 4.68 5.75 6.01 12 13 17 45 16 15 5.58 5.89
Net Cash From Continuing Financing Activities		 4.68 5.75 6.01 12 13 17 45 16 15 5.58 5.89
Repayment of Debt		 -0.82 -0.44 -0.29 -0.48 -1.86 -1.17 0.09 -0.64 -0.60 -0.64 0.00
Issuance of Debt		 5.84 2.33 1.30 0.29 5.47 4.03 - - - 0.00 3.00
Issuance of Preferred Equity		 - - - - 0.00 13 7.11 0.20 5.52 4.50 3.03
Issuance of Common Equity		 0.00 5.28 5.01 12 9.48 0.99 33 23 10 1.73 0.00
Other Financing Activities, net		 - - 0.00 0.00 0.06 0.00 4.91 -6.87 0.00 0.00 -0.14
Effect of Exchange Rate Changes		 - - - - - - - - - - 0.20
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.01 0.11 0.01 0.02 0.02 0.04 0.00

Quarterly Cash Flow Statements for Entero Therapeutics

This table details how cash moves in and out of Entero Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 2.06 0.42 -0.28 -2.77 1.46 -1.96 -0.12 4.46 1.27 -4.90 -0.51
Net Cash From Operating Activities		 -3.33 -3.44 -3.75 -3.45 -1.85 -0.17 -0.82 -0.05 -0.86 -3.97 -1.79
Net Cash From Continuing Operating Activities		 -3.33 -3.44 -3.75 -4.26 0.72 -1.93 -0.82 4.46 -2.09 -7.26 -1.79
Net Income / (Loss) Continuing Operations		 -3.43 -4.10 5.57 -5.57 - -18 -1.26 1.26 - -6.55 -3.44
Consolidated Net Income / (Loss)		 -3.43 -4.10 5.57 - - - -1.26 - - - -3.44
Amortization Expense		 - - - - 0.00 - 0.00 - - 0.37 0.91
Non-Cash Adjustments To Reconcile Net Income		 0.36 0.09 5.08 -14 0.18 15 0.13 2.26 -2.38 0.25 0.74
Changes in Operating Assets and Liabilities, net		 -0.26 0.56 -14 15 0.53 1.48 0.31 0.94 0.30 -1.90 0.00
Net Cash From Investing Activities		 - -0.50 0.09 - - - 0.00 - 0.34 -0.01 0.00
Net Cash From Continuing Investing Activities		 - -0.50 0.09 - - - 0.00 - 0.34 -0.01 0.00
Net Cash From Financing Activities		 5.39 4.36 3.38 0.68 1.55 -0.03 0.70 - 3.03 2.16 1.45
Net Cash From Continuing Financing Activities		 5.39 4.36 3.38 0.68 1.55 -0.03 0.70 - 3.03 2.16 1.45
Repayment of Debt		 -0.15 - -0.23 -0.24 -0.18 - 0.70 - - - 1.00
Other Financing Activities, net		 3.71 -5.95 0.00 0.00 - - 0.00 - - -0.14 0.45
Effect of Exchange Rate Changes		 - - - - - - 0.00 - - - -0.18

Annual Balance Sheets for Entero Therapeutics

This table presents Entero Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 6.69 6.75 5.48 7.47 8.90 13 12 5.44 6.88 85 49
Total Current Assets		 2.07 2.96 1.95 4.80 3.41 7.87 9.42 3.41 4.96 83 2.60
Cash & Equivalents		 0.58 1.77 0.57 1.11 0.18 6.06 8.25 1.36 3.71 0.16 0.90
Accounts Receivable		 1.07 0.96 1.10 3.17 2.64 0.55 0.00 0.09 - 0.00 1.34
Prepaid Expenses		 0.35 0.23 0.27 0.51 0.60 1.26 1.18 1.96 1.24 0.15 0.11
Other Current Assets		 - - - - - - - - - 0.00 0.25
Plant, Property, & Equipment, net		 0.18 0.15 0.13 0.13 0.08 0.02 0.07 0.04 0.01 0.00 0.00
Total Noncurrent Assets		 4.44 3.64 3.39 2.54 5.42 5.04 2.29 1.96 1.89 1.91 46
Goodwill		 1.83 1.77 2.02 1.92 1.89 2.05 1.91 1.68 1.68 1.68 24
Intangible Assets		 2.24 1.53 1.04 0.31 3.41 2.88 - - - 0.00 22
Total Liabilities & Shareholders' Equity		 6.69 6.75 5.48 7.47 8.90 13 12 5.44 6.88 85 49
Total Liabilities		 10 3.54 3.82 3.00 4.29 16 20 2.70 3.28 28 20
Total Current Liabilities		 8.82 2.34 2.48 3.00 4.29 16 12 2.48 3.13 28 15
Short-Term Debt		 6.58 0.16 0.42 0.26 1.52 0.55 0.64 0.60 0.61 0.00 8.28
Accounts Payable		 1.42 2.18 2.06 2.74 2.29 1.69 2.71 0.72 0.55 2.96 3.38
Accrued Expenses		 - - - - - - 0.39 0.32 0.83 0.25 1.43
Dividends Payable		 - - - - - 0.00 0.47 0.76 1.07 1.31 1.65
Other Current Liabilities		 0.82 0.00 - 0.00 0.48 13 8.09 0.08 0.07 0.08 0.42
Total Noncurrent Liabilities		 1.50 1.20 1.34 0.00 0.00 0.02 7.31 0.21 0.15 0.06 4.56
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - - - - - 0.00 4.56
Redeemable Noncontrolling Interest		 - - - - - - - - 0.00 62 3.89
Total Equity & Noncontrolling Interests		 -3.63 3.21 1.66 4.47 4.62 -2.64 -7.82 2.74 3.60 -3.88 25
Total Preferred & Common Equity		 -3.63 3.21 1.66 4.47 4.62 -2.64 -7.82 2.74 3.60 -3.88 20
Preferred Stock		 3.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -7.11 3.21 1.66 4.47 4.62 -2.64 -7.82 2.74 3.60 -3.88 20
Common Stock		 2.53 28 38 53 69 94 147 171 188 199 229
Retained Earnings		 -8.30 -23 -34 -48 -63 -95 -154 -169 -184 -202 -209
Accumulated Other Comprehensive Income / (Loss)		 -1.35 -1.46 -0.96 -1.15 -1.27 -1.11 -1.22 - - 0.00 0.04
Noncontrolling Interest		 - - - - - - - - - 0.00 5.13

Quarterly Balance Sheets for Entero Therapeutics

This table presents Entero Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 5.93 91 86 86 85 85 135 48
Total Current Assets		 3.98 7.49 84 84 83 83 88 2.58
Cash & Equivalents		 3.29 3.43 0.66 0.37 0.06 0.00 2.52 0.39
Accounts Receivable		 0.00 - - - - - 0.04 1.88
Prepaid Expenses		 0.68 4.06 0.55 0.31 0.23 0.14 0.45 0.32
Other Current Assets		 - - - - - - 1.52 0.00
Plant, Property, & Equipment, net		 0.02 0.03 0.00 0.00 0.00 0.00 0.03 0.00
Total Noncurrent Assets		 1.91 84 1.88 1.96 1.73 1.73 48 45
Goodwill		 1.68 20 1.68 1.68 1.68 1.68 26 24
Intangible Assets		 - 0.37 - - - - 22 21
Total Liabilities & Shareholders' Equity		 5.93 91 86 86 85 85 135 48
Total Liabilities		 2.65 13 15 16 29 30 46 20
Total Current Liabilities		 2.48 6.17 15 16 29 30 34 16
Short-Term Debt		 0.00 0.39 0.18 0.00 0.70 0.70 2.70 8.61
Accounts Payable		 0.58 2.00 2.01 2.21 2.85 3.30 4.97 4.07
Accrued Expenses		 0.83 2.55 1.82 0.22 0.30 0.42 0.41 1.28
Dividends Payable		 0.99 1.14 1.17 1.26 1.39 1.47 1.56 1.73
Other Current Liabilities		 0.08 0.10 0.09 0.08 0.27 0.24 0.20 0.54
Total Noncurrent Liabilities		 0.17 7.10 0.10 0.08 0.00 0.00 12 4.24
Noncurrent Deferred & Payable Income Tax Liabilities		 - 0.57 - - - - - 4.24
Redeemable Noncontrolling Interest		 - 62 62 62 62 62 62 3.89
Total Equity & Noncontrolling Interests		 3.28 16 9.12 8.37 -5.22 -6.30 28 24
Total Preferred & Common Equity		 3.28 16 9.12 8.37 -5.22 -6.30 23 19
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3.28 16 9.12 8.37 -5.22 -6.30 23 19
Common Stock		 184 195 197 199 198 198 228 231
Retained Earnings		 -180 -179 -188 -190 -204 -205 -206 -212
Accumulated Other Comprehensive Income / (Loss)		 - - - - - - - 0.05
Noncontrolling Interest		 - - - - - - 5.29 5.01

Annual Metrics And Ratios for Entero Therapeutics

This table displays calculated financial ratios and metrics derived from Entero Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 9,631,088.00 11,554,146.00 16,940,462.00 26,155,111.00 30,412,100.00 12,460,848.00 5,795,404.00 13,499,979.00 4,754,030.00 3,361,903.00
DEI Adjusted Shares Outstanding		 0.00 76.00 92.00 134.00 208.00 241.00 989.00 13,799.00 225,000.00 1,584,677.00 3,361,903.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -130,705.61 -120,612.86 -100,997.14 -72,969.64 -173,163.23 -85,458.63 -1,085.08 -71.57 -11.55 -2.00
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -148.21% 25.36% -22.15% -12.07% -81.22% -126.01% 74.83% -7.90% 1.15% 66.54%
EBIT Growth		 0.00% -131.01% 23.95% -21.05% -13.00% -72.76% -123.21% 75.02% -7.88% 0.98% 60.63%
NOPAT Growth		 0.00% -33.76% -61.60% -31.41% -9.77% -79.28% -123.42% 78.53% -24.39% 0.95% 54.66%
Net Income Growth		 0.00% -146.06% 23.95% -21.96% -12.15% -115.26% -79.17% 75.01% -7.97% -14.34% 63.71%
EPS Growth		 0.00% -37.42% 53.57% 1,484,549,138.46% 45.25% -115.26% -79.17% 75.01% 88.52% -14.34% 73.98%
Operating Cash Flow Growth		 0.00% -8.74% -58.43% -51.29% -29.11% 20.04% -187.73% 30.80% 44.60% 25.53% 38.13%
Free Cash Flow Firm Growth		 0.00% 0.00% -89.93% -62.89% -10.11% 65.35% -686.53% 23.07% 62.84% 18.08% -445.70%
Invested Capital Growth		 0.00% -30.66% -5.68% 139.24% 64.96% -236.69% -83.59% 118.20% -43.00% -183.67% 3,015.44%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 23.45% -12.87% 14.54% -168.98% 9.69% 33.00% -0.70% 15.67% -40.83%
EBIT Q/Q Growth		 0.00% 0.00% 22.11% -11.98% 13.94% -159.51% 9.62% 32.95% -0.70% 15.66% -66.28%
NOPAT Q/Q Growth		 0.00% 0.00% -13.77% -14.65% 16.40% -160.17% 9.54% 41.21% -13.00% 15.61% -96.84%
Net Income Q/Q Growth		 0.00% 0.00% 22.11% -12.83% 15.28% -97.38% 9.62% 32.94% -0.73% -82.01% 58.12%
EPS Q/Q Growth		 0.00% 0.00% 30.67% 2,174,550,804.23% 3,114,661,766.67% -97.38% 9.62% 32.94% -14.19% -82.01% 56.89%
Operating Cash Flow Q/Q Growth		 0.00% -40.18% -6.72% -8.72% 0.81% -31.13% 0.08% 1.20% 14.82% 26.17% -200.04%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -21.21% 1.74% 48.75% -20.03% -3.22% 29.11% 30.72% -27.27%
Invested Capital Q/Q Growth		 0.00% 0.00% 907.95% 227.20% 260.95% -362.53% -8.19% 185.22% 62.09% -291.72% 19.01%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,813.56%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14,367.09%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -19,539.98%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16,962.79%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -18,078.34%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 115.62% 98.70%
Interest Burden Percent		 93.89% 100.00% 100.00% 100.76% 100.00% 124.60% 100.02% 100.05% 100.13% 99.99% 107.98%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -27.12%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -20.75%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 12.00%
Return on Equity (ROE)		 163.38% 7,001.29% -455.37% -441.23% -333.90% -3,305.91% 1,119.03% 576.04% -497.87% -58.82% -15.13%
Cash Return on Invested Capital (CROIC)		 0.00% -190.14% -453.87% -448.98% -264.56% 0.00% 0.00% -975.53% -461.73% 0.00% -116.53%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.18%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9.78%
Return on Common Equity (ROCE)		 319.96% 65,436.61% -455.37% -441.23% -333.90% -3,305.91% 1,119.03% 576.04% -497.87% 0.26% -2.78%
Return on Equity Simple (ROE_SIMPLE)		 163.38% -454.14% -668.22% -302.50% -328.72% 1,237.23% 748.42% -533.51% -438.39% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.31 -4.43 -7.15 -9.40 -10 -19 -41 -8.87 -11 -11 -4.96
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13,677.99%
Net Nonoperating Expense Percent (NNEP)		 44.11% 469.59% -447.68% -818.87% 1,997.99% -680.49% -271.87% -160.72% -459.39% -23.30% -6.37%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -261.87% 282.06% -14.93%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,913.56%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 15,173.44%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,552.98%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 17,726.42%
Earnings before Interest and Taxes (EBIT)		 -6.32 -15 -11 -13 -15 -26 -59 -15 -16 -16 -6.15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -5.58 -14 -10 -13 -14 -26 -58 -15 -16 -16 -5.21
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 14.21 25.31 4.58 5.89 0.00 0.00 1.85 15.74 0.00 0.79
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 9.16 0.00 0.00 0.00 4.80 29.55 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 432.17
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 27.49 27.71 5.43 4.79 0.00 0.00 1.58 34.52 0.00 0.85
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 884.40
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.81 0.05 0.25 0.06 0.33 -0.21 -0.08 0.22 0.17 0.00 0.29
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.64 -10.39 -0.36 -0.16 0.05 -2.11 1.21 1.41 -0.33 -1.00 -0.58
Leverage Ratio		 -1.84 -32.24 2.51 2.11 1.80 11.04 -2.36 -3.39 1.94 1.50 1.55
Compound Leverage Factor		 -1.73 -32.24 2.51 2.13 1.80 13.76 -2.36 -3.39 1.94 1.50 1.67
Debt to Total Capital		 223.15% 4.61% 20.05% 5.39% 24.78% -26.45% -8.93% 18.04% 14.54% 0.00% 22.30%
Short-Term Debt to Total Capital		 223.15% 4.61% 20.05% 5.39% 24.78% -26.45% -8.93% 18.04% 14.54% 0.00% 22.30%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 118.03% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 106.71% 24.30%
Common Equity to Total Capital		 -241.18% 95.39% 79.95% 94.61% 75.22% 126.45% 108.93% 81.96% 85.46% -6.71% 53.40%
Debt to EBITDA		 -1.18 -0.01 -0.04 -0.02 -0.11 -0.02 -0.01 -0.04 -0.04 0.00 -1.59
Net Debt to EBITDA		 -1.06 0.12 0.02 0.07 -0.10 0.21 0.13 0.05 0.20 0.00 -1.42
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -1.99 -0.04 -0.06 -0.03 -0.15 -0.03 -0.02 -0.07 -0.06 0.00 -1.67
Net Debt to NOPAT		 -1.79 0.37 0.02 0.09 -0.13 0.30 0.18 0.09 0.28 0.00 -1.49
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -4.03 -8.88 -10.44 -11.79 -16.60 -34.40 -50.91 -34.37 -3.07 -6.27
Noncontrolling Interest Sharing Ratio		 -95.84% -834.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.45% 81.60%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.23 1.27 0.79 1.60 0.80 0.51 0.77 1.37 1.58 3.03 0.17
Quick Ratio		 0.19 1.17 0.68 1.43 0.66 0.43 0.67 0.59 1.18 0.01 0.15
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -3.72 -7.06 -12 -13 -4.39 -35 -27 -9.87 -8.08 -44
Operating Cash Flow to CapEx		 -17,105.23% -36,704.65% -22,334.74% -3,558.19% -58,235.13% 0.00% -46,465.89% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -112.97 0.00 -0.68 -3,073.13 -1,672.71 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -2.63 0.00 0.00 -106.72 0.00 -1.74 -2,873.90 -1,407.15 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -2.64 0.00 0.00 -109.72 0.00 -1.73 -2,880.08 -1,407.15 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.22
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,668.18
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,668.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.31 1.60 1.51 3.61 5.96 -8.15 -15 2.72 1.55 -1.30 38
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -0.71 -0.09 2.10 2.35 -14 -6.81 18 -1.17 -2.85 39
Enterprise Value (EV)		 0.00 44 42 20 29 24 10 4.29 54 64 32
Market Capitalization		 0.00 46 42 20 27 29 18 5.07 57 2.96 16
Book Value per Share		 ($1.96) $0.33 $0.14 $0.26 $0.18 ($0.09) ($0.63) $0.47 $0.27 ($0.82) $5.89
Tangible Book Value per Share		 ($3.08) ($0.01) ($0.12) $0.13 ($0.03) ($0.25) ($0.78) $0.18 $0.14 ($1.17) ($7.78)
Total Capital		 2.95 3.37 2.08 4.73 6.14 -2.09 -7.18 3.35 4.22 58 37
Total Debt		 6.58 0.16 0.42 0.26 1.52 0.55 0.64 0.60 0.61 0.00 8.28
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 5.94 -1.62 -0.16 -0.86 1.35 -5.51 -7.61 -0.78 -3.12 -0.18 7.38
Capital Expenditures (CapEx)		 0.02 0.01 0.03 0.31 0.02 -0.09 0.07 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.81 -1.00 -0.68 0.95 0.47 -13 -10 0.15 -1.30 56 -5.19
Debt-free Net Working Capital (DFNWC)		 -0.17 0.78 -0.11 2.06 0.64 -7.12 -2.23 1.53 2.44 56 -4.29
Net Working Capital (NWC)		 -6.75 0.62 -0.53 1.80 -0.88 -7.68 -2.88 0.93 1.82 56 -13
Net Nonoperating Expense (NNE)		 2.62 10 3.94 4.13 4.86 14 17 5.75 4.76 7.12 1.60
Net Nonoperating Obligations (NNO)		 5.94 -1.61 -0.15 -0.86 1.35 -5.51 -7.14 -0.02 -2.05 -59 9.03
Total Depreciation and Amortization (D&A)		 0.73 0.73 0.75 0.80 1.02 0.57 0.54 0.03 0.03 0.05 0.94
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14,305.93%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,823.83%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -34,656.82%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($68,460.00) ($94,080.00) ($43,680.00) ($36,960.00) $941,873,688,000.00 $1,194,324,264,000.00 ($39,774.00) ($420.00) ($47.88) $0.00 ($4.16)
Adjusted Weighted Average Basic Shares Outstanding		 86.00 229.00 299.00 0.00 646.00 1.77K 2.13K 35.91K 336.34K 0.00 1.62M
Adjusted Diluted Earnings per Share		 ($68,460.00) ($94,080.00) ($43,680.00) ($36,960.00) $941,873,688,000.00 $1,194,324,264,000.00 ($39,774.00) ($420.00) ($47.88) $0.00 ($4.16)
Adjusted Weighted Average Diluted Shares Outstanding		 86.00 229.00 299.00 0.00 646.00 1.77K 2.13K 35.91K 336.34K 0.00 1.62M
Adjusted Basic & Diluted Earnings per Share		 ($68,460.00) ($94,080.00) ($43,680.00) ($36,960.00) $941,873,688,000.00 $1,194,324,264,000.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 86.00 155.00 253.00 368.00 0.00 0.00 3.98K 77.48K 2.03M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -3.31 -4.43 -7.15 -9.40 -10 -19 -40 -8.87 -11 -11 -4.96
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -13,677.99%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -18,316.78%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3.98 0.00 0.00 -131.88 0.00 -4.06 -5,209.42 -920.85 0.00 0.00 0.00
NOPAT to Interest Expense		 -2.09 0.00 0.00 -92.32 0.00 -2.87 -3,679.56 -558.89 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -3.99 0.00 0.00 -134.88 0.00 -4.05 -5,215.60 -920.85 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2.10 0.00 0.00 -95.32 0.00 -2.85 -3,685.74 -558.89 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -5.74% -9.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Entero Therapeutics

This table displays calculated financial ratios and metrics derived from Entero Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 7,152,204.00 13,499,979.00 2,025,199.00 2,475,090.00 2,475,090.00 4,754,030.00 4,754,030.00 4,765,729.00 4,765,729.00 3,361,903.00 3,361,903.00
DEI Adjusted Shares Outstanding		 119,203.00 225,000.00 675,066.00 825,030.00 825,030.00 1,584,677.00 1,584,677.00 1,588,576.00 1,588,576.00 3,361,903.00 3,361,903.00
DEI Earnings Per Adjusted Shares Outstanding		 -29.22 -18.57 8.15 -10.72 -3.23 -7.76 -0.85 -0.68 -0.78 -0.91 -1.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -177.92% -2.76% -124.04% 18.72% 44.71% 70.78% 89.76% 81.18% 50.65% -126.44% -147.61%
EBIT Growth		 -178.21% -2.75% -123.94% 18.02% 44.79% 70.83% 89.78% 81.38% 50.68% -205.23% -245.54%
NOPAT Growth		 -154.75% -79.57% -123.98% 18.07% 44.87% 70.60% 90.97% 81.35% 50.61% -289.56% -340.05%
Net Income Growth		 -178.20% -2.88% 236.77% -110.25% 24.84% -198.43% -122.62% 88.67% 55.33% 74.32% -173.00%
EPS Growth		 -178.20% 88.67% 101.04% 89.77% 24.84% -198.43% -122.62% 94.56% 57.39% 82.29% 2.38%
Operating Cash Flow Growth		 21.69% 38.50% -31.68% -24.95% 44.51% 95.01% 78.15% 98.41% 53.71% -2,216.74% -118.26%
Free Cash Flow Firm Growth		 -4.94% 91.21% -364.48% 99.64% 99.45% 218.48% 195.84% 161.77% -91,438.54% -2,213.36% -149.77%
Invested Capital Growth		 129.97% -43.00% 4,286.35% -314.17% -134.62% -183.67% -101.77% -30.65% 9,696.39% 3,015.44% 2,668.18%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.40%
EBITDA Q/Q Growth		 17.98% -19.29% -122.36% 62.64% 44.21% 36.95% 22.11% 31.32% -46.32% -189.30% 14.83%
EBIT Q/Q Growth		 17.95% -19.25% -122.26% 62.30% 44.75% 36.99% 22.11% 31.32% -46.32% -289.96% 11.83%
NOPAT Q/Q Growth		 17.90% -19.24% -122.27% 62.35% 44.76% 36.41% 31.75% 22.22% -46.32% -401.55% 22.91%
Net Income Q/Q Growth		 18.02% -19.42% 235.76% -258.20% 70.70% -374.17% 89.71% 20.75% -15.48% -172.63% -9.41%
EPS Q/Q Growth		 18.02% -34.85% 103.06% -1,115.79% 70.70% -374.17% 89.71% 25.00% -257.14% -153.33% 56.84%
Operating Cash Flow Q/Q Growth		 -20.62% -3.25% -8.94% 7.90% 46.43% 90.72% -377.29% 93.30% -1,459.26% -364.38% 55.03%
Free Cash Flow Firm Q/Q Growth		 63.98% 74.15% -5,023.98% 99.93% 44.99% 5,704.65% 4,044.90% -99.95% -81,614.07% -29.40% 2.38%
Invested Capital Q/Q Growth		 28.93% 62.09% 5,206.09% -101.93% 79.16% -291.72% -12.27% -42.53% 1,630.94% 19.01% -1.10%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,813.56% -1,606.31%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,460.09% -6,028.18%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12,933.16% -9,460.06%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -10,055.80% -8,412.46%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,669.77% -8,999.95%
Tax Burden Percent		 100.00% 100.00% -61.19% 256.77% 136.18% 1,024.92% 132.86% 147.91% 118.74% 77.68% 92.03%
Interest Burden Percent		 100.03% 100.17% 100.00% 99.99% 99.99% 99.98% 101.92% 105.65% 103.86% 110.99% 116.24%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -17.95% -27.41%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -18.51% -23.62%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 10.70% 13.49%
Return on Equity (ROE)		 -3,139.91% -497.87% -15.28% -30.06% -27.06% -58.82% -37.05% -27.07% -19.61% -7.26% -13.91%
Cash Return on Invested Capital (CROIC)		 -1,454.04% -461.73% -225.67% 0.00% 0.00% 0.00% 0.00% 0.00% -108.96% -116.53% -122.36%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -5.44% -9.41%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.69% -10.06%
Return on Common Equity (ROCE)		 -3,139.91% -497.87% -3.58% -4.19% -4.30% 0.26% -3.02% -0.61% -3.80% -1.33% -2.22%
Return on Equity Simple (ROE_SIMPLE)		 -478.22% 0.00% -38.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.40 -2.87 -6.37 -2.40 -1.32 -0.84 -0.57 -0.45 -0.65 -3.28 -2.53
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,053.21% -6,622.04%
Net Nonoperating Expense Percent (NNEP)		 -63.71% -119.34% -653.47% -17.67% -3.46% -37.27% -2.56% -0.85% -0.78% 0.56% -3.79%
Return On Investment Capital (ROIC_SIMPLE)		 - -67.97% -27.73% -25.79% -15.83% 21.73% 12.73% 7.99% -2.14% -9.88% -7.86%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,913.56% 1,706.31%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8,658.02% 6,201.26%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,461.59% 1,652.48%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11,119.61% 7,853.74%
Earnings before Interest and Taxes (EBIT)		 -3.43 -4.09 -9.10 -3.43 -1.90 -1.19 -0.93 -0.64 -0.93 -3.65 -3.21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.43 -4.09 -9.09 -3.40 -1.89 -1.19 -0.93 -0.64 -0.93 -2.70 -2.30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 12.65 15.74 0.55 0.33 0.10 0.00 0.00 0.00 0.35 0.79 0.37
Price to Tangible Book Value (P/TBV)		 26.01 29.55 0.00 0.41 0.13 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 432.17 91.21
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 39.86 34.52 0.90 0.00 0.00 0.00 0.00 0.00 2.36 0.85 0.64
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 884.40 321.17
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.82 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.17 0.09 0.00 0.00 0.00 0.01 0.01 0.03 0.29 0.31
Long-Term Debt to Equity		 0.00 0.00 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -3.24 -0.33 0.05 -1.01 -0.99 -1.00 -0.40 -1.03 -0.80 -0.58 -0.57
Leverage Ratio		 10.59 1.94 1.20 1.26 1.25 1.50 1.31 1.36 1.39 1.55 1.59
Compound Leverage Factor		 10.59 1.95 1.20 1.26 1.25 1.50 1.34 1.43 1.44 1.72 1.84
Debt to Total Capital		 0.00% 14.54% 8.02% 0.25% 0.00% 0.00% 1.22% 1.25% 2.93% 22.30% 23.84%
Short-Term Debt to Total Capital		 0.00% 14.54% 0.46% 0.25% 0.00% 0.00% 1.22% 1.25% 2.93% 22.30% 23.84%
Long-Term Debt to Total Capital		 0.00% 0.00% 7.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 72.87% 86.90% 88.05% 106.71% 107.90% 109.98% 72.58% 24.30% 24.66%
Common Equity to Total Capital		 100.00% 85.46% 19.12% 12.85% 11.95% -6.71% -9.13% -11.23% 24.49% 53.40% 51.50%
Debt to EBITDA		 0.00 -0.04 -0.33 -0.01 0.00 0.00 -0.09 -0.15 -0.73 -1.59 -1.20
Net Debt to EBITDA		 0.00 0.20 -0.16 0.03 0.00 0.00 -0.09 -0.15 -0.05 -1.42 -1.15
Long-Term Debt to EBITDA		 0.00 0.00 -0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.06 -0.47 -0.01 0.00 0.00 -0.14 -0.22 -1.07 -1.67 -1.24
Net Debt to NOPAT		 0.00 0.28 -0.23 0.04 0.00 0.00 -0.12 -0.22 -0.07 -1.49 -1.19
Long-Term Debt to NOPAT		 0.00 0.00 -0.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -34.78 -28.77 -2.66 -2.10 -2.19 -2.51 -2.56 -2.60 -1.57 -6.10 -6.55
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 76.55% 86.05% 84.12% 100.45% 91.84% 97.76% 80.60% 81.60% 84.07%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.60 1.58 1.21 5.49 5.34 3.03 2.90 2.81 2.62 0.17 0.16
Quick Ratio		 1.33 1.18 0.56 0.04 0.02 0.01 0.00 0.00 0.08 0.15 0.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.56 -1.69 -87 -0.07 -0.04 2.01 83 0.04 -33 -42 -41
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -6,420.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -3,262.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -3,262.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.22 0.39
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,668.18 938.60
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,668.18 -938.60
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.96 1.55 82 -1.59 -0.33 -1.30 -1.46 -2.08 32 38 37
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.15 -1.17 80 -2.33 -1.29 -2.85 -84 -0.49 32 39 39
Enterprise Value (EV)		 38 54 74 64 62 64 65 64 75 32 24
Market Capitalization		 41 57 8.87 3.04 0.85 2.96 2.28 1.91 7.94 16 6.79
Book Value per Share		 $0.46 $0.27 $7.99 $3.69 $3.38 ($0.82) ($1.10) ($1.32) $4.74 $5.89 $5.53
Tangible Book Value per Share		 $0.22 $0.14 ($2.08) $3.00 $2.70 ($1.17) ($1.45) ($1.67) ($5.25) ($7.78) ($7.97)
Total Capital		 3.28 4.22 85 71 70 58 57 56 92 37 36
Total Debt		 0.00 0.61 6.78 0.18 0.00 0.00 0.70 0.70 2.70 8.28 8.61
Total Long-Term Debt		 0.00 0.00 6.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -3.31 -3.12 3.35 -0.51 -0.39 -0.18 0.63 0.69 0.18 7.38 8.22
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.82 -1.30 -1.73 68 68 56 55 54 54 -5.19 -5.43
Debt-free Net Working Capital (DFNWC)		 1.49 2.44 1.70 69 68 56 55 54 57 -4.29 -5.04
Net Working Capital (NWC)		 1.49 1.82 1.32 69 68 56 55 54 54 -13 -14
Net Nonoperating Expense (NNE)		 1.03 1.24 -12 6.41 1.26 11 0.68 0.55 0.50 -0.14 0.91
Net Nonoperating Obligations (NNO)		 -2.32 -2.05 4.49 -72 -70 -59 -58 -57 -58 9.03 9.95
Total Depreciation and Amortization (D&A)		 0.01 0.01 0.01 0.04 0.00 0.00 0.00 0.00 0.00 0.94 0.91
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14,305.93% -7,289.15%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,823.83% -6,771.36%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -34,656.82% -18,328.61%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.46) ($12.42) $3.12 ($3.86) ($1.77) ($32.19) ($0.84) ($0.21) ($0.75) ($1.90) ($0.82)
Adjusted Weighted Average Basic Shares Outstanding		 7.57M 336.34K 1.76M 2.29M 1.52M 381.66K 1.59M 4.77M 1.65M 1.62M 4.45M
Adjusted Diluted Earnings per Share		 ($0.46) ($12.42) $0.38 ($3.86) ($1.77) ($32.19) ($0.84) ($0.21) ($0.75) ($1.90) ($0.82)
Adjusted Weighted Average Diluted Shares Outstanding		 7.57M 336.34K 14.51M 2.29M 1.52M 381.66K 0.00 4.77M 1.65M 1.62M 4.45M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($12.42) $0.00 $0.00 $0.00 ($32.19) $0.00 $0.00 $0.00 ($1.90) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.50M 2.03M 2.48M 0.00 1.58M 0.00 1.59M 4.77M 3.36M 0.00 6.65M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.40 -2.87 -6.37 -2.40 -1.32 -0.84 -0.57 -0.45 -0.65 -3.28 -2.53
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -9,053.21% -6,622.04%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11,161.41% -9,778.92%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -3,362.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -2,353.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -3,362.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -2,353.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Entero Therapeutics (NASDAQ: GRDX) is showing a familiar early-stage biotech profile: minimal revenue, persistent operating losses, and heavy reliance on financing to stay liquid. The latest quarter, Q1 2026, did include some signs of improvement versus prior periods, but the company still burned cash and remains far from breakeven.

  • Cash balance improved versus the prior quarter. Entero ended Q1 2026 with $385,542 in cash and equivalents, up from $251,721 in Q3 2025 and above the $4,474 reported in Q2 2025.
  • Operating loss narrowed sharply year over year. Q1 2026 operating loss was $3.6 million, better than Q4 2025’s $4.7 million and far below the much larger losses seen in 2024.
  • Operating expenses were lower than in late 2025. Q1 2026 total operating expenses of $3.0 million were down from $4.0 million in Q4 2025.
  • Financing helped offset the cash burn. The company generated $1.45 million of net cash from financing activities in Q1 2026, which partially softened the operating outflow.
  • Losses have improved from the 2024 reset period. Quarterly losses in 2026 and 2025 are much smaller than the very large impairment-heavy results seen in 2024, suggesting the business has moved away from some of the most distressed historical periods.
  • Revenue remains extremely small. Q1 2026 revenue was just $38,208, which is not enough to cover even a fraction of expenses.
  • Gross margin is still deeply negative. Cost of revenue was $651,948 against only $38,208 of revenue, producing a gross loss of $613,740.
  • R&D spending is modest relative to SG&A. Q1 2026 R&D expense was $631,380, while SG&A was $2.37 million, indicating the cost structure is still heavily weighted toward overhead rather than product development.
  • Non-cash charges are meaningful. Amortization expense of $910,983 helped reduce reported earnings pressure, but these charges do not improve underlying cash generation.
  • Cash from operations was negative. Q1 2026 operating cash flow was a deficit of $1.79 million, showing the core business is still consuming cash.
  • Quarterly net loss remains large. Entero reported a Q1 2026 net loss of $3.44 million, or $(0.82) per share.
  • Working capital pressure remains elevated. Current liabilities of $16.23 million exceeded current assets of $2.58 million in Q1 2026, suggesting short-term balance sheet stress.
  • Debt and other obligations are significant relative to liquidity. The company reported $8.61 million in short-term debt, plus $1.73 million in dividends payable and $4.07 million in accounts payable.
  • Equity attributable to common shareholders is still modest after losses. Common equity was $18.59 million in Q1 2026, but retained earnings remained deeply negative at $(212.1) million.
  • Recent quarters show continued dependence on outside funding. Q4 2025 and earlier periods included debt issuance, preferred equity issuance, and other financing support to keep cash balances from collapsing.

Bottom line: Entero Therapeutics has made some progress in trimming losses and stabilizing liquidity, but the business is still operating at a cash loss with very limited revenue. For retail investors, this remains a highly speculative name where survival and future financing capacity matter just as much as clinical or commercial execution.

08/06/26 01:51 PM ETAI Generated. May Contain Errors.

Entero Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Entero Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Entero Therapeutics' net income appears to be on an upward trend, with a most recent value of -$6.55 million in 2025, rising from -$5.93 million in 2015. The previous period was -$18.06 million in 2024.

Entero Therapeutics' total operating income in 2025 was -$7.08 million, based on the following breakdown:
  • Total Gross Profit: -$657.43 thousand
  • Total Operating Expenses: $6.43 million

Over the last 10 years, Entero Therapeutics' total revenue changed from $0.00 in 2015 to $36.25 thousand in 2025, a change of 3,625,100.0%.

Entero Therapeutics' total liabilities were at $19.72 million at the end of 2025, a 28.6% decrease from 2024, and a 91.2% increase since 2015.

In the past 10 years, Entero Therapeutics' cash and equivalents has ranged from $163.48 thousand in 2024 to $8.25 million in 2021, and is currently $899.78 thousand as of their latest financial filing in 2025.

Over the last 10 years, Entero Therapeutics' book value per share changed from -1.96 in 2015 to 5.89 in 2025, a change of -400.8%.


Related Companies

Financial statements for NASDAQ:GRDX last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SMX: A Tiny Ticker with a Massive Global Growth Story!
SMX (Security Matters) is building molecular tagging technology that verifies recycled materials from collecti...
Smallcaps Daily | Sponsoredtc pixel
A Wall Street Veteran's Weekly Trade for Any Market Condition
Dave Aquino spent 25 years at Merrill Lynch and Vanguard studying one weekly options play that worked in bull,...
Base Camp Trading | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
A $5 stock inside Kennedy Space Center?
A small publicly traded company operates a specialized launch vehicle fleet inside the secure perimeter of Ken...
Freedom Financial | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel